Literature DB >> 19349877

Rosiglitazone, a PPAR-gamma ligand, reduces burn progression in rats.

Breena R Taira1, Adam J Singer, Steve A McClain, Fubao Lin, Jean Rooney, Tom Zimmerman, Richard A F Clark.   

Abstract

Burns induce the activation of an inflammatory cascade that generates reactive oxygen radicals and lipid peroxidation leading to burn wound progression and extension. Peroxisome proliferation-activated receptor-gamma is a nuclear hormone receptor that is activated by transcription factors and plays an important role in the regulation of cellular proliferation and inflammation. We hypothesized that treatment of burns with rosiglitazone, a peroxisome proliferation-activated receptor-gamma ligand, would reduce burn wound progression. This is a randomized controlled study of 20 Sprague-Dawley rats. Two burns were created on each animal's dorsum using a brass comb with four rectangular prongs preheated in boiling water and applied for 30 seconds resulting in four rectangular 10 x 20 mm full thickness burns separated by three 5 x 20 mm unburned interspaces (zone of ischemia). Animals were randomized to rosiglitazone 4 mg/kg or vehicle by oral gavage 30 minutes after injury and at 24 and 48 hours after injury. Wounds were observed at 1, 2, 3, and 4 days after injury for visual evidence of necrosis in the unburned interspaces. Full thickness biopsies from the interspaces were evaluated with hematoxylin and eosin staining 7 days after injury for evidence of necrosis. The percentage of interspaces that progressed to necrosis was compared with chi tests. Forty comb burns with 120 unburned interspaces were evenly distributed between rosiglitazone and vehicle. The number of interspaces that progressed to full thickness necrosis at 1, 2, 3, 4, and 7 days after injury in the rosiglitazone and vehicle groups were 9/60 (15%) versus 13/60 (21%) (P = .48), 16/60 (27%) versus 15/60 (20%) (P = 1.00), 24/60 (40%) versus 46/60 (77%) (P = .001), 35/60 (58%) versus 53/60 (88%) (P = .001), and 43/60 (72%) versus 54/60 (90%) (P = .02), respectively. Treatment with oral rosiglitazone reduces the percentage of unburned skin interspaces that progress to full necrosis in a rat comb burn model.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19349877     DOI: 10.1097/BCR.0b013e3181a28e37

Source DB:  PubMed          Journal:  J Burn Care Res        ISSN: 1559-047X            Impact factor:   1.845


  7 in total

Review 1.  Novel pharmacotherapy for burn wounds: what are the advancements.

Authors:  Michael R Hamblin
Journal:  Expert Opin Pharmacother       Date:  2018-12-05       Impact factor: 3.889

2.  In vitro 3D full-thickness skin-equivalent tissue model using silk and collagen biomaterials.

Authors:  Evangelia Bellas; Miri Seiberg; Jonathan Garlick; David L Kaplan
Journal:  Macromol Biosci       Date:  2012-11-19       Impact factor: 4.979

3.  Topically applied metal chelator reduces thermal injury progression in a rat model of brass comb burn.

Authors:  Cheng Z Wang; Amina El Ayadi; Juhi Goswamy; Celeste C Finnerty; Randy Mifflin; Linda Sousse; Perenlei Enkhbaatar; John Papaconstantinou; David N Herndon; Naseem H Ansari
Journal:  Burns       Date:  2015-09-29       Impact factor: 2.744

4.  Validation of a vertical progression porcine burn model.

Authors:  Adam J Singer; Douglas Hirth; Steve A McClain; Laurie Crawford; Fubao Lin; Richard A F Clark
Journal:  J Burn Care Res       Date:  2011 Nov-Dec       Impact factor: 1.845

Review 5.  The molecular mechanisms of action of PPAR-γ agonists in the treatment of corneal alkali burns (Review).

Authors:  Hongyan Zhou; Wensong Zhang; Miaomiao Bi; Jie Wu
Journal:  Int J Mol Med       Date:  2016-08-04       Impact factor: 4.101

Review 6.  The Immune and Regenerative Response to Burn Injury.

Authors:  Matthew Burgess; Franklin Valdera; David Varon; Esko Kankuri; Kristo Nuutila
Journal:  Cells       Date:  2022-09-29       Impact factor: 7.666

7.  Dual therapeutic functions of F-5 fragment in burn wounds: preventing wound progression and promoting wound healing in pigs.

Authors:  Ayesha Bhatia; Kathryn O'Brien; Mei Chen; Alex Wong; Warren Garner; David T Woodley; Wei Li
Journal:  Mol Ther Methods Clin Dev       Date:  2016-06-22       Impact factor: 6.698

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.